Business, energy, technology, markets and global industry news from Business News Today

Children’s Hospital of Philadelphia

PharmaDeviceNews Children’s Hospital of Philadelphia
Infographic showing Latus Bio’s preclinical AAV delivery data, highlighting capsids reaching 80% of kidney glomeruli and up to 60% of cortical neurons, while noting that human safety and efficacy remain unproven.
Pharma & Biotech

Latus Bio’s new AAV capsids reach 80% of kidney glomeruli, but can better delivery translate into safer gene therapies?

Latus Bio reports AAV capsids reaching 80% of kidney glomeruli and up to 60% of cortical neurons, with human safety and efficacy unproven.

Read More
Synaptiq Therapeutics is advancing the acquired SYN-001 clinical programme toward a Phase IIb trial targeting neuropsychiatric symptoms associated with 22q11.2 deletion syndrome. Representative image.
Pharma & Biotech

What Synaptiq Therapeutics’ SYN-001 acquisition means for 22q11.2 deletion syndrome

Synaptiq Therapeutics acquires SYN-001 and plans a Phase IIb trial for neuropsychiatric symptoms in 22q11.2 deletion syndrome.

Read More